Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK

Approval Announcement: Camurus has received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Oczyesa®, a once-monthly subcutaneous octreotide treatment for adult patients with acromegaly.

Clinical Efficacy: The approval is based on results from a comprehensive clinical program, including two Phase 3 studies, demonstrating effective control of acromegaly and improved patient quality of life.

Self-Administration Feature: Oczyesa® can be self-administered using a pre-filled autoinjector pen, making it convenient for patients to manage their treatment at home.

Future Developments: Camurus plans to launch Oczyesa® in the UK in the fourth quarter of 2025 and is also developing CAM2029 for other severe diseases, including gastroenteropancreatic neuroendocrine tumors and polycystic liver disease.